SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule...
With a new year on the horizon, a clutch of companies have decided on new names for 2024. Pipeline Therapeutics has become Contineum Therapeutics, while Novozymes and Chr. Hansen have picked Novonesis as their new shared identity.
Pipeline Therapeutics Changes Name to Contineum Therapeutics
Pipeline Therapeutics to Participate in Upcoming Investor Conferences
Pipeline Therapeutics to Participate in Multiple Upcoming Investor Conferences
Pipeline Therapeutics Announces First Subject Dosed with PIPE-791 in Phase 1 Study
SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today announced that the U.S. Food and Drug Administration (FDA) cleared the company to initiate its Phase 1 clinical trial of PIPE-791 in healthy volunteers. The Company’s wholly owned program, PIPE-791, is a potent, selective and brain-penetrant small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1). LPA1 is a critical element in bioactive phospholipid signaling, and is a powerful mediator of both nervous system and systemic inflammatory conditions. Specifically, LPA1 inhibition has important therapeutic potential through augmentation of remyelination and mitigation of neuro-inflammation. Multiple sclerosis (MS) is a leading indication for PIPE-791, as there are no currently approved medicines designed to prevent neuronal loss and mitigate clinical disability in MS patients.
SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that Carmine Stengone, CEO of Pipeline, will present on June 9, 2023 at 12:15pm ET at the 2023 Jefferies Global Healthcare Conference, being held June 7-9, 2023 in New York, NY. Company management will also participate in one-on-one meetings with investors during the conference.
SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that Carmine Stengone, CEO of Pipeline, will present on Tuesday, May 16, 2023 at 4:05 pm ET at the RBC Global Healthcare Conference, being held May 16-17, 2023 in New York, NY. Company management will also participate in one-on-one meetings with investors during the conference.
Pipeline Therapeutics Announces Participation at the 2023 Stifel CNS Days Conference